Sanofi says LixiLan diabetes drug trials meet targets

PARIS (Reuters) - France's Sanofi said on Sunday that two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe early next year.